New Zealand - engelsk - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - pseudoephedrine hydrochloride 120mg - modified release capsule - 120 mg - active: pseudoephedrine hydrochloride 120mg excipient: ammonio methacrylate copolymer dibutyl phthalate maize starch methacrylic acid copolymer purified talc stearic acid sucrose

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - macrogol 4000 55 mg/ml - oral solution - 55 g/l - active: macrogol 4000 55 mg/ml excipient: soluble lemon essence potassium chloride saccharin sodium sodium bicarbonate sodium chloride sodium sulfate water for injection

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ephedrine sulfate 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine sulfate 30 mg/ml excipient: sodium chloride water for injection

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dopamine hydrochloride 40 mg/ml;   - solution for injection - 200 mg/5ml - active: dopamine hydrochloride 40 mg/ml   excipient: sodium metabisulfite water for injection - latest regulatory activity

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 500 mcg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: benzalkonium chloride hydrochloric acid monobasic sodium phosphate monohydrate propylene glycol purified water sodium edetate sodium hydroxide

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 500 mcg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: benzalkonium chloride hydrochloric acid monobasic sodium phosphate monohydrate propylene glycol purified water sodium edetate sodium hydroxide

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - oxymetazoline hydrochloride 0.25 mg/ml - nasal drops - 250 mcg/ml - active: oxymetazoline hydrochloride 0.25 mg/ml excipient: benzalkonium chloride cherry flavour 051849 c glycine propylene glycol purified water sodium hydroxide sorbitol

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

marketing brokers nz ltd - oxymetazoline hydrochloride 0.5 mg/ml - nasal spray solution - 0.5 mg/ml - active: oxymetazoline hydrochloride 0.5 mg/ml excipient: benzalkonium chloride monobasic sodium phosphate dihydrate purified water sodium chloride sorbitol - dimetapp 12 hour nasal spray is long acting for up to 12 hours, relieving nasal congestion due to colds, sinusitis, hayfever and other respiratory allergies.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

wyeth consumer healthcare a division of wyeth (nz) limited - pseudoephedrine hydrochloride 60mg - liquid filled capsule - 60 mg - active: pseudoephedrine hydrochloride 60mg excipient: allura red ac brilliant blue fcf gelatin macrogol 400 povidone propylene glycol purified water sorbitol

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

max health limited - dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml;   - concentrate for infusion - 12.5 mg/ml - active: dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml   excipient: hydrochloric acid sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin: a. acute heart failure acute myocardial infarction, cardiogenic shock, following cardiac surgery, medicine-induced depression of cardiac contractility such as that which occurs in excessive ?-adrenergic receptor blockade. b. chronic heart failure acute decompensation of chronic congestive heart failure, temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin: acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure, low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). paediatric population: dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock. dobutamine stress echocardiography: dobutamine hydrochloride may be used as a substitute for physical exercise in stress testing in the diagnosis of coronary artery disease. precautions apply (refer to data sheet).